Follow the オンコリスバイオファーマ株式会社 stock price and the full insider trade history of the company, a publicly traded company based in Japan. Shares trade on the JP market, under the supervision of EDINET (Japan FSA). Market capitalisation: €72.9bn. The latest transaction was disclosed on 5 February 2026 (Holding update). Among the most active insiders: SMBC Nikko Securities Inc.. Every trade is openly available.
31
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
17Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,166 of 29,053 companies
38.8
score / 100
Value
27
Quality
51
FCF yld-2.7%
Earn yld-2.8%
EV/EBITDA·
ROE-110%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Oncolis BioPharma Inc. es una empresa biofarmacéutica japonesa centrada en el desarrollo de tratamientos innovadores contra el cáncer. Se especializa en la investigación y comercialización de terapias basadas en virus oncolíticos.